P93: Lumateperone (ITI-007), a novel drug in development for the Treatment of Agitation in Patients with Dementia, Including Alzheimer's Disease: Rationale and Clinical Trial Design
Robert Davis Ph.D.¹, Kimberly Vanover Ph.D.¹, Cedric O’Gorman MD¹, Jelena Saillard¹, Michal Weingart Ph.D.¹, Sharon Mates Ph.D.¹

P94: Alzheimer's Disease Cooperative Study (ADCS) Multicenter Trail: Prazosin for Agitation in Alzheimer's Disease (PEACE-AD)
Elaine R. Peskind, MD¹,², Murray A. Raskind, MD¹,², Howard Feldman, MD, FRCP³,⁴, for the Alzheimer’s Disease Cooperative Study
(1)VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center (MIRECC), Seattle/American Lake, WA, USA (2)University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA (3)Alzheimer’s Disease Cooperative Study, San Diego, CA, USA (4) University of California, San Diego, Department of Neurosciences, San Diego, CA, USA

P95: Neuropsychiatric symptoms and the risk of conversion to dementia among MCI subjects
Maria Soto, MD, PhD¹, Simon Dietlin, MD¹, Vera Kiyasova PhD², Maria Pueyo, MD, PhD², Adélaïde de Mauleton, MD¹, Julien Delrieu, MD¹, Pierre Jean Ousset, MD¹, Bruno Vellas, MD, PhD¹
(1) Gerontopôle, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, France (2) Institut de Recherches Internationales Servier, Suresnes, France

P96: Natural History, Epidemiology, Neurobiology, Burden, and Unmet Needs of Agitation in Alzheimer’s Disease: Where are we now? A Systematic Review
Chuidian M¹, Waterman F¹, Bird S¹, De Jong-Laird A¹, Baker R¹, Me genomic T¹
(1) Avanir Pharmaceuticals Inc, Aliso Viejo, CA (2) Xcenda, Palm Harbor, Fl (3) Otsuka Pharmaceutical Europe Ltd. (OPEL), Gallions, Wexham Springs (4) Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC), Princeton, NJ